A flame retardant for thermosetting resin containing an aromatic phosphoric acid ester represented by the general formula (I): ##STR00001##
wherein R.sup.1 to R.sup.4 each independently represent a hydrogen atom, a C.sub.1-4 alkyl group, or a C.sub.1-4 alkoxy group; R.sup.5, R.sup.6, and R.sup.9 each independently represent a C.sub.1-10 alkyl group or a C.sub.1-10 alkoxy group; R.sup.7 and R.sup.8 each independently represent a C.sub.1-4 alkyl group or a C.sub.1-4 alkoxy group; n represents an integer of 1 to 10; n.sup.1 and n.sup.2 each independently represent an integer of 0 to 3; m.sup.1 and m.sup.2 each independently represent an integer of 0 to 4; p represents an integer of 0 to 26; and k represents an integer of 1 to 12; and when p is 2 or more, any two substituents R.sup.9 may be bonded to each other, and may be bonded to a carbon atom(s) of a ring to which the above substituents R.sup.9 are bonded, forming another ring.

Disclosed is the compound vitamin D.sub.3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound. Also disclosed are methods of treating vitamin D deficiency using the compound. The compound is particularly suitable for transdermal delivery.

An efficient and commercial phosphorylation process of a complex alcohol, such as secondary and tertiary alcohols, with P.sub.4O.sub.10 at high temperatures, and a product obtained by the process.

A process a process of forming a non-halogenated flame retardant (FR) hindered amine light stabilizer (HALS) cross-linker is disclosed. The process includes forming a mixture that includes a first molecule having a hindered amine group. The first molecule corresponds to a functionalized 2,2,6,6-tetramethylpiperidine (TMP) molecule. The process also includes forming the non-halogenated FR HALS cross-linker via a chemical reaction of the first molecule a second molecule. The second molecule includes a phosphoryl group, a chloride group, and at least one cross-linkable (CL) moiety.

A process a process of forming a non-halogenated flame retardant (FR) hindered amine light stabilizer (HALS) cross-linker is disclosed. The process includes forming a mixture that includes a first molecule having a hindered amine group. The first molecule corresponds to a functionalized 2,2,6,6-tetramethylpiperidine (TMP) molecule. The process also includes forming the non-halogenated FR HALS cross-linker via a chemical reaction of the first molecule a second molecule. The second molecule includes a phosphoryl group, a chloride group, and at least one cross-linkable (CL) moiety.

A method for producing an asymmetric phosphoric acid triester using a flow reactor, the method including step (A1) of reacting phosphorus trichloride or phosphorus tribromide with a first hydroxy compound; step (B1) of reacting the compound obtained in the step (A1) with a second hydroxy compound; step (C1) of reacting the compound obtained in the step (B1) with a third hydroxy compound; and step (D1) of oxidizing the compound obtained in the step (C1), in which the reaction temperature in the steps (A1) and (B1) is ?80? C. or higher, and in the steps (A1) and (B1), the flow rate of each of the phosphorus trichloride or phosphorus tribromide, the first hydroxy compound, and the second hydroxy compound flowing in a flow channel is 0.01 mL/min or more.

A process a process of forming a non-halogenated flame retardant (FR) hindered amine light stabilizer (HALS) cross-linker is disclosed. The process includes forming a mixture that includes a first molecule having a hindered amine group. The first molecule corresponds to a functionalized 2,2,6,6-tetramethylpiperidine (TMP) molecule. The process also includes forming the non-halogenated FR HALS cross-linker via a chemical reaction of the first molecule a second molecule. The second molecule includes a phosphoryl group, a chloride group, and at least one cross-linkable (CL) moiety.

Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.